Download PDF

Diabetologia

, Volume 31, Issue 4, pp 235–240 | Cite as

Abnormal regulation of pancreatic glucagon secretion in obese fa/fa rats

  • F. Rohner-Jeanrenaud
  • B. Jeanrenaud
Originals
Received:
Revised:

Summary

The results reported in the literature regarding glucagonaemia in genetically obese fa/fa rats are conflicting: normal, increased or decreased plasma glucagon levels have been reported. Due to the existence of several molecules endowed with glucagon-like immunoreactivity, it was thought that the conflicting data could be related to the degree of specificity of the different glucagon antibodies. Three antibodies that all qualified as being specific for pancreatic glucagon were used. It was found that, depending on the antibody, absolute values of basal glucagonaemia or arginine-induced glucagon output varied quantitatively and qualitatively in both lean and obese rats. When non-extracted basal or stimulated plasma samples were passed on a G-50 Sephadex column, glucagon-like immunoreactivity was present over a wide range of molecular weights, indicating the presence of non-pancreatic glucagon molecules. When an ethanol extraction was used, the fractions eluting from the G-50 Sephadex column contained only pancreatic glucagon immunoreactivity. It is concluded that ethanol extraction is necessary for the measurement of the 3500 daltons glucagon. Using this methodology it was found that: (1) basal glucagonaemia was low but identical in the two groups of rats; (2) arginine-induced glucagon secretion was greater in obese than in lean animals; (3) glucagonaemia was decreased by glucose administration in lean but not in obese rats. It is concluded that there are, in obese animals, dysfunctions of glucagon output that may play a role in their abnormal glucose tolerance.

Key words

fa/fa rats glucagon output pancreatic glucagon ethanol extraction specific antiglucagon antibodies 
Download to read the full article text

References

  1. 1.
    Rohner-Jeanrenaud F, Jeanrenaud B (1985) Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity. Endocrinology 116: 830–834Google Scholar
  2. 2.
    Zucker LM, Antoniades HN (1972) Insulin and obesity in the Zucker genetically obese rat “fatty”. Endocrinology 90: 1320–1330Google Scholar
  3. 3.
    Assimacopoulos-Jeannet F, Jeanrenaud B (1976) The hormonal and metabolic basis of experimental obesity. Clin Endocrinol Metab 5: 337–365Google Scholar
  4. 4.
    Jeanrenaud B, Halimi S, van de Werve G (1985) Neuroendocrine disorders seen as triggers of the triad: obesity — insulin resistance — abnormal glucose tolerance. Diabetes Metab Rev 1: 261–291Google Scholar
  5. 5.
    Jeanrenaud B (1985) An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause. Diabetologia 28: 502–513Google Scholar
  6. 6.
    Eaton RP, Conway M, Schade DS (1976) Endogenous glucagon regulation in genetically hyperlipemic obese rats. Am J Physiol 230 (5): 1336–1341Google Scholar
  7. 7.
    Bryce GF, Johnson PR, Sullivan AC, Stern JS (1977) Insulin and glucagon: plasma levels and pancreatic release in the genetically obese Zucker rat. Horm Metab Res 9: 366–370Google Scholar
  8. 8.
    Hayek A, Woodside W (1979) Correlation between morphology and function in isolated islets of the Zucker rat. Diabetes 28: 565–569Google Scholar
  9. 9.
    Conlon JM (1980) The glucagon-like polypeptides-order out of chaos? Diabetologia 18: 85–88Google Scholar
  10. 10.
    Starke AAR, Erhardt G, Berger M, Zimmermann H (1984) Elevated pancreatic glucagon in obesity. Diabetes 33: 277–280Google Scholar
  11. 11.
    Heding LG (1971) Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7: 10–19Google Scholar
  12. 12.
    Von Schenck H, Nilsson OR (1981) Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta 109: 183–191Google Scholar
  13. 13.
    Rosselin G, Assan R, Yalow RS, Berson SA (1966) Separation of antibody bound and unbound peptide hormones labelled with iodine 131 by talcum powder and precipitated silica. Nature 212: 355–357Google Scholar
  14. 14.
    Wilson MA (1977) Radioimmunoassay of insulin. In: Abraham GE (ed) Handbook of radioimmunoassay. Dekker, New York Basel, pp 275–297Google Scholar
  15. 15.
    Von Schenck H (1983) Increased specificity of plasma glucagon radioimmunoassay by use of acetone extraction. Clin Chim Acta 127: 41–46Google Scholar
  16. 16.
    Assan R, Attali JR, Ballerio B, Boillot J, Girard JR (1977) Glucagon secretion induced by natural and artificial amino acids in the perfused rat pancreas. Diabetes 26: 300–307Google Scholar
  17. 17.
    Unger RH, Lefebvre PJ (1972) Glucagon physiology. In: Lefebvre PJ, Unger RH (eds) Glucagon: molecular physiology, clinical and therapeutic implications. Pergamon Press, Oxford New York Toronto Sydney Braunschweig, pp 213–244Google Scholar
  18. 18.
    Eaton RP, Oase R, Schade DS (1976) Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of therapy? Metabolism 25 (3): 245–249Google Scholar
  19. 19.
    Werner PL, Palmer JP (1978) Immunoreactive glucagon responses to oral glucose, insulin infusion and deprivation, and somatostatin in pancreatectomized man. Diabetes 27: 1005–1012Google Scholar
  20. 20.
    Nishikawa K, Ikeda H, Matsuo T (1981) Abnormal glucagon secretion in Zucker fatty rats. Horm Metab Res 13: 259–263Google Scholar
  21. 21.
    Mayer J, Andrus SB, Silides DJ (1953) Effect of diethyldithiocarbamate and other agents on mice with the obese-hyperglycemic syndrome. Endocrinology 53: 572–581Google Scholar
  22. 22.
    Flatt PR, Bailey CJ, Buchanan KD (1982) Regulation of plasma immunoreactive glucagon in obese hyperglycaemic (ob/ob) mice. J Endocrinol 95: 215–227Google Scholar
  23. 23.
    Bobbioni E, Coscelli C (1980) Portal levels of glucagon and insulin in VMH-lesioned rats. Horm Metab Res 12: 480–481Google Scholar
  24. 24.
    Goto Y, Carpenter RG, Berelowitz M, Frohman LA (1980) Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas. Metabolism 29: 986–990Google Scholar
  25. 25.
    Rohner-Jeanrenaud F, Jeanrenaud B (1984) Oversecretion of glucagon by pancreases of ventromedial hypothalamic-lesioned rats: a re-evaluation of a controversial topic. Diabetologia 27: 535–539Google Scholar
  26. 26.
    Heding LG, Rasmussen SM (1972) Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects. Diabetologia 8: 408–411Google Scholar
  27. 27.
    Alford FP, Bloom SR, Nabarro JDN (1977) Glucagon levels in normal and diabetic subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay. Diabetologia 13: 1–6Google Scholar
  28. 28.
    Borghi VC, Wajchenberg BL, Cesar FP (1984) Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism 33: 1068–1074Google Scholar
  29. 29.
    Reaven GM, Chen Y-DI, Golay A, Swislocki ALM, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106–110Google Scholar
  30. 30.
    Unger RH (1978) Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27: 1691–1709Google Scholar
  31. 31.
    Ionescu E, Sauter JF, Jeanrenaud B (1985) Abnormal oral glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol 248: E500-E506Google Scholar
  32. 32.
    Rohner-Jeanrenaud F, Proietto J, Ionescu E, Jeanrenaud B (1986) Mechanism of abnormal oral glucose tolerance of genetically obese (fa/fa) rats. Diabetes 35: 1350–1355Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • F. Rohner-Jeanrenaud
    • 1
  • B. Jeanrenaud
    • 1
  1. 1.Laboratoires de Recherches Métaboliques, Faculty and Department of MedicineUniversity of GenevaSwitzerland

Personalised recommendations